Tests a metabolic care clinic for people with severe mental illness
Tests a metabolic care clinic for adults with schizophrenia or bipolar disorder.
Plain-language title generated from the registry record
Registry title: Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic
Key facts
- Where
- Glostrup Municipality, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT06624462, who can take part
Where in Denmark
- Centre for Neuropsychiatric Schizophrenia Research, CNSR, Mental Health Centre GlostrupGlostrup Municipality, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bjorn H. Ebdrup
- Trial code
- NCT06624462
- Record updated
- 8 January 2026
- Original description
This study will examine the effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental IllnessRead full original descriptionShow less
Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic
This study will examine the effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness
Inclusion: Patients with schizophrenia spectrum disorders (International classification of diseases; ICD-10: DF2x) or bipolar disorder (ICD-10: DF30.x or DF31.x); Medical treatment with antipsychotics; Age 18-45 years; Legally competent; Able to give informed consent; and either:; Body mass index (BMI) ≥30 kg/m2; Or; BMI ≥27 kg/m2 and at least one of the following:; Hypertension defined as treatment with ≥1 antihypertensive drug or out-of-office / 24-hour, non-invasive ambulatory blood pressure ≥140/90 mmHg within the previous 6 months; Dyslipidaemia defined as treatment with ≥1 lipid-lowering drug or elevated low-density lipoprotein (LDL) cholesterol (≥3.0 mmol/l), elevated triglycerides (≥1.7 mmol/l) or low high-density lipoprotein cholesterol (≥1.2 mmol/l in women and ≥1.0 mmol/l in men) within the previous 6 months; Sleep apnoea (ICD-10 DG473); Prediabetes or diabetes defined as HbA1c ≥42 mmol/mol or impaired fasting glucose as defined by the International Diabetes Federation within the previous 6 months; Or; a history of rapid weight gain during antipsychotic therapy defined as increases of either ≥5% body weight or ≥5 cm waist circumference since initiation of antipsychotic therapy.
Exclusion: Severe current drug or alcohol misuse as judged by the research team; Unstable psychiatric disorder as judged by the research team; Clinical or laboratory evidence of comorbid medical disease not compatible with participation as judged by the research team; Acute suicidal risk.